Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2006

View Archived Issues

Snapshots on the antineoplastic effects of farnesyltransferase inhibitors

Degarelix achieves positive phase IIb results, enters phase III development

CRx-119 misses endpoint in exploratory immunoinflammatory disease model

EvoGenix inlicenses anticancer antibody

Genelabs draws up protocol for additional Prestara trial

New phase II study begins for GLP-1 agonist AVE-0010

Praecis enters pilot study and option agreement with GSK

Forest and Almirall sign U.S. agreement for COPD treatment LAS-34273

Enrollment terminated in GENASIS trial

Adventrx and SD Pharmaceuticals sign definitive merger agreement

Pharmacyclics acquires therapeutic programs from Celera Genomics

Quigley to begin clinical studies for QR-333

Pharmos awarded Israeli grant for CB2-selective drug development

BL-1020 for schizophrenia studied in phase I trial

Rufinamide efficacy revealed in partial seizures

Indiplon improves insomnia

Studies evaluate FTY-720 in humans, investigate mechanism of action

Analyses show noninferiority of faropenem antibiotic efficacy

Resistant pneumococcal disease declined after introduction of conjugate vaccine

Bivalent human papillomavirus vaccine provides long-term protection

NXL-101 evaluated in phase I study

Silenor gives statistically significant improvements in wake after sleep onset

Ambrisentan improves exercise capacity in PAH patients

Supplemental BLA submitted for Avastin in NSCLC

Novel 5-HT6 agonists from Wyeth presented at ACS

S1P receptor agonists emerge from Praecis R&D

New treatment strategies for cancer covered in recent patents

Indena synthesizes water-soluble camptothecin analogue with promising profile

Chiron presents preclinical data on its selective Raf kinase inhibitor CHIR-265

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.